Pharmacists in Pisgah Forest, NC Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Ms. Leslie Worthington Firth, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 45 Hendersonville Hwy, Pisgah Forest, NC 28768 Phone: 828-884-8404 |
Dr. Elaine Bertha Long, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 Black Walnut Ln, Pisgah Forest, NC 28768 Phone: 828-862-8932 |
Samantha J Martin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 45 Hendersonville Hwy, Pisgah Forest, NC 28768 Phone: 828-884-8404 |
 Teklu Abraha Woldemichael Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 45 Hendersonville Hwy, Pisgah Forest, NC 28768 Phone: 828-884-8404 |
Ben R Hallman, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 177 Forest Gate Ctr, Pisgah Forest, NC 28768 Phone: 828-885-7904 |
Lawrence Craig Meads, BS PHARMACY Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 210 Forest Gate Ctr, Pisgah Forest, NC 28768 Phone: 828-862-6885 Fax: 828-862-6885 |
News Archive
PTSD impairs ability to recognize emotions from facial expressions
Facial expressions convey strong cues for someone's emotional state and the ability to interpret these cues is crucial in social interaction. This ability is known to be compromised in many psychiatric and neurological disorders, such as social anxiety or Korsakoff's syndrome.
Study gives insights into how better clinical trials can address ‘critically low' dementia research
New research gives insights into how the design of clinical trials can improve to address the "critically low" research pipeline and improve the chances of finding effective dementia therapies.
American Medical Group Association to participate in COPD care management
The American Medical Group Association (AMGA) and the American Medical Group Foundation (AMGF) are pleased to announce an opportunity for AMGA members to participate in a learning collaborative on care management for patients with COPD. The Best Practices Learning Collaborative is for organizations that are striving to improve the care of patients with COPD.
Endo responds to FDA Complete Response letter for FORTESTA NDA
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.
› Verified 2 days ago